The <i>Ighmbp2</i>D564N mouse model is the first SMARD1 model to demonstrate respiratory defects
C E Smith, Monique A. Lorson, Sara M. Ricardez Hernandez, Zayd Al Rawi, Jiude Mao, José Marquez, Eric Villalón, Amy N. Keilholz, Catherine L. Smith, Mona O. Garro-Kacher, Toni I. Morcos, Daniel J. Davis, Elizabeth C. Bryda, Nicole L. Nichols, Christian L. Lorson
Abstract
Spinal muscular atrophy with respiratory distress type I (SMARD1) is a neurodegenerative disease defined by respiratory distress, muscle atrophy and sensory and autonomic nervous system defects. SMARD1 is a result of mutations within the IGHMBP2 gene. We have generated six Ighmbp2 mouse models based on patient-derived mutations that result in SMARD1 and/or Charcot-Marie Tooth Type 2 (CMT2S). Here we describe the characterization of one of these models, Ighmbp2D564N (human D565N). The Ighmbp2D564N/D564N mouse model mimics important aspects of the SMARD1 disease phenotype, including motor neuron degeneration and muscle atrophy. Ighmbp2D564N/D564N is the first SMARD1 mouse model to demonstrate respiratory defects based on quantified plethysmography analyses. SMARD1 disease phenotypes, including the respiratory defects, are significantly diminished by intracerebroventricular (ICV) injection of ssAAV9-IGHMBP2 and the extent of phenotypic restoration is dose-dependent. Collectively, this model provides important biological insight into SMARD1 disease development.